CD274 and small cell lung carcinoma: Phase III studies have demonstrated that integrating PD‐L1 inhibitors, such as atezolizumab and durvalumab, with chemotherapy significantly enhances OS in previously untreated ES SCLC patients, when compared to chemotherapy alone.